Press Release
SoftBank Focuses On The Layout Of The Metaverse With AOS To Create A Brand-New Future
Recently, Softbank Ventures Asia publicly announced that it has begun to focus on Metaverse and invested in the AOS project. It will cooperate with AOS to connect and integrate more Metaverses in AI, NFT, robotics, and other fields, and carry the development of large-scale killer applications.
The enthusiastic investment in Metaverse has not subsided, but it has risen again. The technology giants have all entered the Metaverse. Facebook plans to fully transform into Metaverse before 2025, and will set up a product team to accelerate investment in VR/AR and the creator community; Bytedance, which has always believed in Striving for Miracles, merged Mutong Technology for 4 billion USD, and begin to lay out the Metaverse; Axie Infinity builds NFT games based on the Metaverse, subverting the traditional game mode and becoming a phenomenon-level game product; miHOYO, the developer of “Genshin Impact”, formed an AI scientist inverse entropy team, and self-developed Avatar Luming to explore the brain-computer interface. Through investment, miHOYO has successfully deployed the social Metaverse Soul; the Internet industry is renewing and iterating rapidly, and companies need to attach importance to meet unknown concepts and challenges or be left behind by the times.
In the Metaverse era, everything has virtual avatars. The concept of Metaverse seems to be still in the mist today, but the prelude to the new era has been opened, and it is closer than you think.
The popularization of the term Metaverse was cited from the novel Avalanche by American science fiction writer Neil Stephenson in 1992. In his book, he used the word Metaverse for the first time without foundation and described it as a parallel universe projected from the real world through technical means such as the Internet. However, anyone who has watched the movie “Ready Player One” by the great director Steven Spielberg should probably understand this concept. Like the “Oasis” in the movie, the company has created a realistic virtual world outside of the real world. Every player in the real world has another identity in the virtual world, establishes another social circle, and leads another life. Although the Metaverse is only a virtual world, its immersion is so vivid that you will think it is the real world and enjoy life in this new world.
AOS (Artificial Intelligence Operating System) is the first operating system developed by Canada Unicorn Park, based on the underlying blockchain technology to connect the Metaverse. By building a Metaverse bridge online, and using robots as an intelligent carrier offline to build an ecosystem between Metaverses and provide a new experience for integration with Metaverse and the real world.
Based on AOS, users could create an AI NFT that has autonomous consciousness and advanced self-learning capability; And it also gets influenced by the distributed personality database on the chain to build character, and gradually complete neural network-style self-learning and improvements. Most of all, the distributed character database is based on the “Book of Changes” and appropriately constructs the character of AI; users can inject their favorite characters, personalities, voices, etc., into their own AI NFT, and tame it to learn more skills. AOS encourages users to integrate more characters and personalities, combined with NFT to create different artistic values. The custom AI itself has NFT attributes. Users can customize the appearance of AI on the network, and can also authorize access to a third-party character customization system, such as specific character images and voices, and third-party NFT star voices and appearances, packaged in the form of NFT used for trading and collection.
AOS connects the first-generation physical carrier, the AI four-wheel driving robot Mars_1 with the Metaverse and the real world, creating a new user experience.
Mars_1 is a highly integrated artificial intelligence robot product. Its appearance is in the form of a four-legged driving robot dog. It adopts an original five-layer motion control technology and several technical indicators are in a leading position in the global industry. Mars_1 has integrated the Internet of Things, 5G, virtual reality/augmented reality, intelligent driving, swarm intelligence, and other technologies. Mars_1 will obey commands and gradually be closer to a dog and then become to a good assistant to humankind.
On the road to the Metaverse, AOS always hopes to leave a strong and colorful stroke in its own way. Connect the Metaverse through AI and map out the experience and lifestyle of the future. For the world that people dream of, high-intelligence AI coupled with linkage with robots will be an indispensable component of this era. As the aboriginal and basic units of the Metaverse, these virtual species based on AOS will continue to establish connections with us beyond human beings in the infinite space and time of the future, transcending the fetters of races.
Sun Zhengyi believes: “We are about to experience the biggest change in human history. AI will eventually replace human beings. This is not only reflected in knowledge but also in intelligence. This change will happen in this century, and then in the next 30 years, there is no doubt that our focus is on AI, intelligent robots, and the IOTs.” Based on this analysis and judgment, SoftBank has frequently carried out large-scale layouts in the fields of AI, intelligent robots, and IOTs. Start from all aspects to create a powerful robot empire. Today, SoftBank’s industries have completed the layout of the future of the new Internet field as Sun Zhengyi said in the past, and completed more than half of the investment of unicorn companies on a global scale, laying a foundation for the subsequent development of the IOTs in the world.
As a world-renowned “Animation Kingdom”, Japan has an irreplaceable influence in the global animation field. After half a century of development, the Japanese animation industry has formed an extremely large system, making Japan the world’s largest animation production and exporting country, and it also around animation IP to derive cultural and creative products, such as GK. With the development of smart technology, they also work hard in the direction of intelligence for GK. Headquartered in Japan, SoftBank has a unique geographical location and is deeply immersed in Japanese IP culture. This collaboration with AOS will further promote the combination of the GK industry and the AIindustry, and provide AOS with a steady stream of IP resources. Users’ favorite characters such as Luffy, Conan, Sailor Moon, Sakuragi Hanamichi, Inuyasha, etc., can inject their image and personality into AI to create your smart figure. Each AI figure is a unique individual, and different parameters also create different expressions and styles. At the same time, when users have more exchanges with AI, they will gradually become familiar with the user’s temper and preferences and adjust their apparent personality in real-time and dynamically making it infinitely close to the form that we want to see eventually.
The product made by a single company is not enough to be called a Metaverse but constitutes an ecological system. With the deep participation of users, if it is successful in collective efforts to build a more interoperable system, and it can be transformed into different layers, then it should be called a Metaverse. AOS is committed to becoming the link between the physical world and the virtual world, as a bridge between various Metaverses to connect the Metaverse and continue to build a new Metaverse ecology. This will be the top priority in the next stage of the development of the Internet after the mobile Internet.
What kind of world will mankind be in the future? SoftBank Asia and AOS have worked together because of the same concept for Metaverse and jointly created such a grand concept, standing at the forefront of the Metaverse economic tide, seizing opportunities, embracing the new future, and believing that with their win-win cooperation, they will give a perfect answer for the world.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot
Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.
AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.
The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“
Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.
“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“
The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.
Media Contact
Company: AI Labs
Contact: Media Team
Email: ryan@academic-labs.org
Website: https://ai-labs.live/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.
The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.
The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.
Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options
Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.
Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.
Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.
More Information About Povorcitinib Phosphate Tablets
Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.
A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).
About CMS
CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.
CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.
CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.
Reference
1、China Insights Consultancy (CIC) report
2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
ONAR’s Largest Acquisition Closed With Two Days Left in Q3
NYC, New York, November 19th, 2026, FinanceWire
ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.
Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.
What Advertise Purple brings to ONAR
The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.
ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.
Why the Nasdaq application matters
ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.
At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.
That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.
For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.
About ONAR Holding Corporation
ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.
Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.
Learn more at https://www.onar.com/
Contact
President
Craig Fischer
ValueCorp
cf@valuecorptrading.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release1 week ago
Midwest Ragdolls Explains Why Playful Kitten Biting Is Often Misunderstood
-
Press Release2 days ago
OiLChef Wins Restaurant Solution of the Year Award at 2026 Restaurant & Takeaway Innovation Expo
-
Press Release1 week ago
ARCPE Holding, LLC Highlights the Importance of Understanding Local Real Estate Market Conditions
-
Press Release7 days ago
Red Banyan CEO Evan Nierman Leads High-Stakes Communications Workshop at NASDDDS Annual Conference
-
Press Release6 days ago
IntelliVIX Wins Two CES 2027 Innovation Awards, Showcasing Global Competitiveness in Safety AI
-
Press Release6 days ago
Rifstone Capital LLC Advances Institutional Research Platform with Expanded Global Allocation Framework
-
Press Release1 week ago
Dasher Personalized Running Highlights Personalized Half Marathon Training Plans Focused on Injury Prevention and Sustainable Progress
-
Press Release6 days ago
Eurotrace net Unveils New Blockchain Intelligence Research Initiative
